Xeomin®
BRCA2 Mutation
Mayo ClinicPhase 3Dormant
B
59/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 48/ 100
- Competitive Position
- 81/ 100
Competitive context
16 Active assets in the BRCA2 Mutation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Olaparib GBG Forschungs GmbH | Phase 3 | BB |
Ovitrelle University Hospital, Ghent | Phase 4 | BB |
Carboplatin Okayama University | Phase 2 | B |
Niraparib University of California, San Francisco | Phase 2 | B |
Irinotecan University of California, San Francisco | Phase 2 | B |
View all 24 →
Same molecule, other indications
Xeomin® is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →